Trials / Completed
CompletedNCT00287547
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 144 (planned)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, pharmacokinetics and clinical activity and immunogenicity of BMS-188667 (CTLA4Ig) in subjects with psoriasis vulgaris
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CTLA4Ig / Abatacept |
Timeline
- Start date
- 1997-03-01
- Primary completion
- 1998-01-01
- Completion
- 1998-01-01
- First posted
- 2006-02-07
- Last updated
- 2011-04-25
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00287547. Inclusion in this directory is not an endorsement.